? Medix Biochemica全資收購(gòu)全球領(lǐng)先的體外診斷用基質(zhì)生產(chǎn)商美國(guó)Bioresource Technology Inc. （以下簡(jiǎn)稱(chēng)“BRT”）
Medix?Biochemica?has acquired 100 percent of the shares of USA-based?Bioresource Technology Inc. ("BRT"), a leading provider of base matrices for the in vitro diagnostics ("IVD") manufacturing industry?worldwide??
? 通過(guò)此次并購(gòu)，BRT和Medix Biochemica集團(tuán)高度互補(bǔ)的產(chǎn)品線可全方位滿足體外診斷質(zhì)控品關(guān)鍵原料的需求，并通過(guò)Medix Biochemica的既有網(wǎng)絡(luò)為全球合作伙伴提供服務(wù)
As a result of the acquisition, the highly complementary portfolios of BRT and Medix Biochemica now provide a complete offering of critical raw materials for IVD quality control ("QC") products which will be available?through Medix Biochemica's comprehensive global sales network?
? 此次并購(gòu)是Medix Biochemica集團(tuán)實(shí)現(xiàn)其成為體外診斷關(guān)鍵原料首選合作伙伴這一戰(zhàn)略愿景的又一個(gè)重要里程碑，可幫助合作伙伴達(dá)到其原料供應(yīng)鏈整合的目標(biāo)。
The acquisition is another important step in the execution of Medix Biochemica's strategy to be the first-choice raw material partner to the IVD industry?and help customers' goal to further consolidate their supply chain.
2022年6月20日，芬蘭埃斯波 – Medix Biochemica宣布全資收購(gòu)Bioresource Technology (簡(jiǎn)稱(chēng)“BRT”) 以擴(kuò)充其體外診斷用基質(zhì)原料產(chǎn)品線，并進(jìn)一步強(qiáng)化其在美國(guó)市場(chǎng)的力量。此次并購(gòu)?fù)瓿珊?，Medix Biochemica將為其合作伙伴提供全面的的IVD質(zhì)控品原料。BRT的組織和運(yùn)營(yíng)將和Medix Biochemica集團(tuán)既有的位于密蘇里州圣路易斯的天然抗原、酶、蛋白和生物樣本的生產(chǎn)一起，成為體外診斷生物材料部門(mén)的重要組成部分。BRT的日常運(yùn)營(yíng)將繼續(xù)保留在佛羅里達(dá)州韋斯頓(Weston)進(jìn)行。BRT主席Derik Reichenbach和首席運(yùn)營(yíng)官Ron Dilling將在并購(gòu)后成為集團(tuán)的戰(zhàn)略顧問(wèn)。
Espoo, Finland, June 20, 2022 - Medix Biochemica has acquired 100 percent of the shares of Bioresource Technology (“BRT”) to broaden its base matrix capabilities and further strengthen its local presence in the US market. As a result of this partnership, Medix Biochemica will provide its customers with a comprehensive offering of raw materials for their IVD quality control products. The organization and operations of BRT will form a significant part of Medix Biochemica's IVD Biomaterials Business Unit, which also comprises manufacturing of native antigens, enzymes, proteins and biologicals in St. Louis, Missouri. BRT's operations will stay in Weston, Florida, and BRT’s President Derik Reichenbach and CEO Ron Dilling will remain as strategic advisors following the acquisition.??
BRT由David Reichenbach博士于1984年創(chuàng)立，是高品質(zhì)基質(zhì)及其它體外診斷關(guān)鍵原料的領(lǐng)先供應(yīng)商，高度專(zhuān)注于為全球免疫、臨床生化、分子診斷、及質(zhì)控品生產(chǎn)商提供原料和服務(wù)。公司位于美國(guó)佛羅里達(dá)州韋斯頓，共有約20名極富經(jīng)驗(yàn)的專(zhuān)業(yè)人員，場(chǎng)地約兩萬(wàn)六千平方英尺，所有產(chǎn)品均采用全球領(lǐng)先的工藝進(jìn)行生產(chǎn)，且生產(chǎn)體系經(jīng)過(guò)ISO 13485:2016認(rèn)證。
Founded in 1984 by Dr. David Reichenbach, BRT is a leading provider of high-quality base matrices and other critical raw materials for the IVD industry, with a sharp focus on immunoassay, clinical chemistry and molecular diagnostic assay and QC material manufacturers worldwide. The company manufactures its products in a state of the art, ISO 13485:2016 certified, 26,000 square foot facility in Weston, Florida and it employs a highly skilled team of approximately 20 professionals.
“通過(guò)并購(gòu)，我們得以為全球體外診斷公司提供更寬廣的產(chǎn)品線。本次并購(gòu)，兩個(gè)公司的產(chǎn)品線完美互補(bǔ)。這讓Medix Biochemica集團(tuán)成為有高質(zhì)量質(zhì)控品原料需求的IVD公司的全面合作伙伴。基于全面的產(chǎn)品線，包括生物樣本、加工后的血漿、基質(zhì)、天然酶、蛋白、抗體、抗原等，以及我們對(duì)行業(yè)和技術(shù)深刻的理解，無(wú)論IVD公司需要什么，我們都可以極大地縮短其產(chǎn)品開(kāi)發(fā)、上市所需的時(shí)間。我們的愿景是成為體外診斷行業(yè)首選合作伙伴，BRT團(tuán)隊(duì)的加入讓我們離實(shí)現(xiàn)此愿景更近一步”，Medix Biochemica集團(tuán)首席執(zhí)行官Steve Ferguson說(shuō)。
“Together, we have the potential to broaden our offering to IVD companies across the globe. There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products. With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need. Our vision is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer,” says Steve Ferguson, CEO of Medix Biochemica.?
“加入Medix Biochemica集團(tuán)讓我們無(wú)比激動(dòng)”，BRT主席Derik Reichenbach說(shuō)，“一直以來(lái)，與客戶建立長(zhǎng)期關(guān)系都是我們成功的關(guān)鍵。加入Medix Biochemica全球化的團(tuán)隊(duì)以后，我們將有機(jī)會(huì)與全球更多客戶建立聯(lián)系。非常期待我們的加入可以讓Medix Biochemica的增長(zhǎng)更加強(qiáng)勁?！?/span>
“We are excited about joining Medix Biochemica”, says Derik Reichenbach, President of BRT. “Building long-term relationships with our customers have always been key to our success and together with Medix Biochemica's global team, we are now able to reach even more IVD customers across the globe. We are very much looking forward to contributing to the strong growth of Medix Biochemica”.?
如需更多信息，請(qǐng)聯(lián)系:
For more information:
Medix Biochemica中國(guó)商務(wù)團(tuán)隊(duì)
Commercial Team of Medix Biochemica China
Tel +86 21 6811 9180, 6811 9181, 6811 9105
Email: medixchina@medixbiochemica.com
關(guān)于BRT
Bioresource Technology LLC.是全球領(lǐng)先的供應(yīng)商，供應(yīng)高質(zhì)量、大批量的加工后血漿及血清基質(zhì)，為體外診斷質(zhì)量控制相關(guān)產(chǎn)品（諸如質(zhì)控品、校準(zhǔn)品、標(biāo)準(zhǔn)品、及實(shí)驗(yàn)室能力考核等）的開(kāi)發(fā)和生產(chǎn)提供關(guān)鍵原料。BRT專(zhuān)注于與試劑廠商合作，提供度身定制的解決方案，滿足其對(duì)基質(zhì)各種復(fù)雜、嚴(yán)苛而關(guān)鍵的要求，并可以迅速放大生產(chǎn)以支持客戶快速增長(zhǎng)的需要。
關(guān)于Medix Biochemica
作為一家芬蘭公司，Medix Biochemica 是體外診斷行業(yè)全球領(lǐng)先的關(guān)鍵原料供應(yīng)商，在世界各地增長(zhǎng)迅速。我們?yōu)槿蚝献骰锇殚_(kāi)發(fā)、生產(chǎn)、供應(yīng)高品質(zhì)抗體、抗原及其它體外診斷關(guān)鍵原料，助力全球數(shù)十億患者得到精準(zhǔn)診斷結(jié)果。從免疫診斷到分子診斷，從生物樣本到定制服務(wù)，我們的專(zhuān)長(zhǎng)覆蓋體外診斷的方方面面。在IVD行業(yè)，我們擁有全球最全的產(chǎn)品線，久經(jīng)歷煉的團(tuán)隊(duì)，我們已經(jīng)做好一切準(zhǔn)備，幫助我們的客戶縮短產(chǎn)品上市所需時(shí)間、通過(guò)提供高品質(zhì)原料和服務(wù)為每一個(gè)試劑盒的質(zhì)量提供堅(jiān)實(shí)保障。不管是哪個(gè)疾病領(lǐng)域，不管是哪種應(yīng)用，在IVD領(lǐng)域，只要您有任何需要，都可能是我們合作的契機(jī)。Medix Biochemica集團(tuán)在全球擁有約300名專(zhuān)業(yè)的員工，通過(guò)我們?cè)谥袊?guó)、北美、和歐洲的本地團(tuán)隊(duì)，我們?yōu)槿蚩蛻籼峁┓?wù)。
聯(lián)系我們
上海墨迪斯醫(yī)療技術(shù)有限公司 │ 上海市閔行浦江綠洲環(huán)路10號(hào)6幢(2號(hào)樓)11層
電話: +86 21 6811 9180, 6811 9181, 6811 9105 │ 傳真: +86 21 6811 9125
郵箱: medixchina@medixbiochemica.com │ 網(wǎng)址: onb2b.cn